These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 21185752)

  • 21. A new algorithm to predict warfarin dose from polymorphisms of CYP4F2 , CYP2C9 and VKORC1 and clinical variables: derivation in Han Chinese patients with non valvular atrial fibrillation.
    Wei M; Ye F; Xie D; Zhu Y; Zhu J; Tao Y; Yu F
    Thromb Haemost; 2012 Jun; 107(6):1083-91. PubMed ID: 22534826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Influence of clinical and genetic factors on warfarin dose requirements among Japanese patients.
    Ohno M; Yamamoto A; Ono A; Miura G; Funamoto M; Takemoto Y; Otsu K; Kouno Y; Tanabe T; Masunaga Y; Nonen S; Fujio Y; Azuma J
    Eur J Clin Pharmacol; 2009 Nov; 65(11):1097-103. PubMed ID: 19582440
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development and comparison of a warfarin-dosing algorithm for Korean patients with atrial fibrillation.
    Cho HJ; On YK; Bang OY; Kim JW; Huh W; Ko JW; Kim JS; Lee SY
    Clin Ther; 2011 Oct; 33(10):1371-80. PubMed ID: 21981797
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Contribution of VKORC1 and CYP2C9 polymorphisms in the interethnic variability of warfarin dose in Malaysian populations.
    Gan GG; Phipps ME; Lee MM; Lu LS; Subramaniam RY; Bee PC; Chang SH
    Ann Hematol; 2011 Jun; 90(6):635-41. PubMed ID: 21110192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Pharmacogenetic impact of VKORC1 and CYP2C9 allelic variants on warfarin dose requirements in a hispanic population isolate.
    Palacio L; Falla D; Tobon I; Mejia F; Lewis JE; Martinez AF; Arcos-Burgos M; Camargo M
    Clin Appl Thromb Hemost; 2010 Feb; 16(1):83-90. PubMed ID: 19567378
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.
    Scott SA; Jaremko M; Lubitz SA; Kornreich R; Halperin JL; Desnick RJ
    Pharmacogenomics; 2009 Aug; 10(8):1243-55. PubMed ID: 19663669
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VKORC1 and CYP2C9 genotype and patient characteristics explain a large proportion of the variability in warfarin dose requirement among children.
    Biss TT; Avery PJ; Brandão LR; Chalmers EA; Williams MD; Grainger JD; Leathart JB; Hanley JP; Daly AK; Kamali F
    Blood; 2012 Jan; 119(3):868-73. PubMed ID: 22010099
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Warfarin pharmacogenetics: development of a dosing algorithm for Omani patients.
    Pathare A; Al Khabori M; Alkindi S; Al Zadjali S; Misquith R; Khan H; Lapoumeroulie C; Paldi A; Krishnamoorthy R
    J Hum Genet; 2012 Oct; 57(10):665-9. PubMed ID: 22854539
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A warfarin-dosing model in Asians that uses single-nucleotide polymorphisms in vitamin K epoxide reductase complex and cytochrome P450 2C9.
    Tham LS; Goh BC; Nafziger A; Guo JY; Wang LZ; Soong R; Lee SC
    Clin Pharmacol Ther; 2006 Oct; 80(4):346-55. PubMed ID: 17015052
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Predicting the warfarin maintenance dose in elderly inpatients at treatment initiation: accuracy of dosing algorithms incorporating or not VKORC1/CYP2C9 genotypes.
    Moreau C; Pautas E; Gouin-Thibault I; Golmard JL; Mahé I; Mulot C; Loriot MA; Siguret V
    J Thromb Haemost; 2011 Apr; 9(4):711-8. PubMed ID: 21255252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interactive modeling for ongoing utility of pharmacogenetic diagnostic testing: application for warfarin therapy.
    Linder MW; Bon Homme M; Reynolds KK; Gage BF; Eby C; Silvestrov N; Valdes R
    Clin Chem; 2009 Oct; 55(10):1861-8. PubMed ID: 19679631
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Validation of pharmacogenetic algorithms and warfarin dosing table in Egyptian patients.
    Bazan NS; Sabry NA; Rizk A; Mokhtar S; Badary O
    Int J Clin Pharm; 2012 Dec; 34(6):837-44. PubMed ID: 22851439
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical significance of combined CYP2C9 and VKORC1 genotypes in Japanese patients requiring warfarin.
    Miyagata Y; Nakai K; Sugiyama Y
    Int Heart J; 2011; 52(1):44-9. PubMed ID: 21321468
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pharmacogenetics of oral anticoagulants: a basis for dose individualization.
    Stehle S; Kirchheiner J; Lazar A; Fuhr U
    Clin Pharmacokinet; 2008; 47(9):565-94. PubMed ID: 18698879
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Estimation of warfarin maintenance dose based on VKORC1 (-1639 G>A) and CYP2C9 genotypes.
    Zhu Y; Shennan M; Reynolds KK; Johnson NA; Herrnberger MR; Valdes R; Linder MW
    Clin Chem; 2007 Jul; 53(7):1199-205. PubMed ID: 17510308
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
    Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
    Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of CYP2C9 and VKORC1 genotypes on early-phase and steady-state warfarin dosing in Korean patients with mechanical heart valve replacement.
    Kim HS; Lee SS; Oh M; Jang YJ; Kim EY; Han IY; Cho KH; Shin JG
    Pharmacogenet Genomics; 2009 Feb; 19(2):103-12. PubMed ID: 19077919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Accuracy assessment of pharmacogenetically predictive warfarin dosing algorithms in patients of an academic medical center anticoagulation clinic.
    Shaw PB; Donovan JL; Tran MT; Lemon SC; Burgwinkle P; Gore J
    J Thromb Thrombolysis; 2010 Aug; 30(2):220-5. PubMed ID: 20204461
    [TBL] [Abstract][Full Text] [Related]  

  • 39. CYP4F2 rs2108622: a minor significant genetic factor of warfarin dose in Han Chinese patients with mechanical heart valve replacement.
    Cen HJ; Zeng WT; Leng XY; Huang M; Chen X; Li JL; Huang ZY; Bi HC; Wang XD; He YL; He F; Zhou RN; Zheng QS; Zhao LZ
    Br J Clin Pharmacol; 2010 Aug; 70(2):234-40. PubMed ID: 20653676
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New genetic variant that might improve warfarin dose prediction in African Americans.
    Schelleman H; Brensinger CM; Chen J; Finkelman BS; Rieder MJ; Kimmel SE
    Br J Clin Pharmacol; 2010 Sep; 70(3):393-9. PubMed ID: 20716240
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.